Original Publication Date: 1 January, 2017
Publication / Source: Future Oncology
Authors: Maliha Khan, Maryam Sarfraz & Naval Daver
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) represent a unique subset of hematopoietic stem cell tumors characterized by clinical, morphologic and laboratory features of both MDS and MPN. According to the 2008 WHO classification, these myeloid neoplasms include four hematopathologic entities, namely chronic myelomonocytic leukemia (CMML), BCR–ABL1-negative atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia (JMML) and MDS/MPNs unclassifiable (MDS/MPN-U) as well as a provisional entity of refractory anemia with ring sideroblasts and thrombocytosis (RARS-T).